As New Drug Modalities Advance, WuXi AppTec Expands Global Capabilities for Peptides, Oligonucleotides and TPDs

▤ Summary

WuXi AppTec is expanding global manufacturing and technology capabilities for peptides, oligonucleotides, targeted protein degraders, and ADCs. The company is adding capacity across regions, including new TIDES plants in China and Singapore, to support growing demand for complex drug modalities. It is also investing in process technologies that improve scalability, purification, and product quality. The update shows WuXi AppTec building capacity ahead of demand as next-generation drug programs move toward commercialization.

▦ Linked Companies